BioSpace News Archive

Mustang Bio, Inc. announced that an abstract reporting on Phase 1 trials being conducted at the UAB and City of Hope of Mustang Bio’s exclusively licensed oncolytic viral and CAR T-cell therapies for the treatment of patients with glioblastoma, has been selected as a late-breaking poster presentation at the AACR Annual Meeting 2022, taking place April 8 – 13, 2022, in New Orleans, Louisiana.

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that dosing has begun in a Phase 1/2 clinical trial of DNL593 (PTV:PGRN) for the potential treatment of frontotemporal dementia (FTD) caused by mutations in the granulin gene (GRN).

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will present two late-breaking posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans, LA.

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that chairman and CEO Dr. Hans S. Keirstead will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place March 9-11 in San Diego.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced key strategic and operational results for the year ended December 31, 2021.

Vicore Pharma Holding AB, a clinical-stage pharmaceutical company developing medicines targeting the Angiotensin II type 2 receptor, announces plans to initiate a clinical trial with C21 in PAH.

International medical imaging IT and cybersecurity company Sectra’s radiology module for enterprise imaging, Sectra PACS, received a top ranking in customer satisfaction surveys in the US, Canada and Asia/Oceania.

Sirona Biochem Corp. is pleased to announce that its wholly owned subsidiary TFChem, has been awarded financing to develop an advanced chemistry process that could improve the manufacturing of active ingredients.

ITM Isotope Technologies Munich SE announced the presentation of the design for its second phase III trial, COMPOSE at the 19th Annual European Neuroendocrine Tumor Society Conference being held in a hybrid format in Barcelona on March 10-11, 2022.

TScan Therapeutics, Inc. reported financial results for the full year ended December 31, 2021, and outlined key 2022 priorities.